(Q47957463)

7 February 2018

http://europepmc.org/abstract/MED/9632001

title

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial (English)

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

main subject

phase II clinical trial

0 references

multicenter clinical trial

1 reference

4

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

author name string

J Bagel

1

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

W T Garland

2

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

D Breneman

3

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

T W Littlejohn

5

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

D Crosby

6

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

H Faust

7

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

D Fivenson

8

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

J Nichols

9

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

language of work or name

English

0 references

publication date

1 June 1998

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

published in

Journal of the American Academy of Dermatology

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

volume

38

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

issue

6 Pt 1

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

page(s)

938-944

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

cites work

The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Cloning of the gamma chain of the human IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Intracellular pathway of interleukin 2 following receptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970590-0

7 January 2021

10.1016/S0190-9622(98)70590-0

Identifiers

DOI

1 reference

7 February 2018

http://europepmc.org/abstract/MED/9632001

1 reference

7 February 2018